Drug Alerts and Special Reports

Key reimbursement alerts for office-administered drugs — C-Code, J-Code, NDC, and NCCN alerts plus pricing updates, sent on behalf of pharma manufacturers.

Subscribe To Newsletter

Biosimilar 04/20/2023

Samsung Bioepis Biosimilar Market Report (Q2 2023) - 4/19/23

To support all the stakeholders involved in this exciting journey of biosimilars in the US, Samsung Bioepis will bring you this Samsung Bioepis Biosimilar Market Report. The Samsung Bioepis Biosimilar Market Report will be published quarterly in conjunction with the release of the CMS ASP file. In the 1 st edition of the Samsung Bioepis Biosimilar Market Report, we provide an in-depth analysis of pricing and market share trends in the US market and for the following biosimilar categories: Oncology / Supportive Care / Immunology / Ophthalmology / Endocrinology We will also review the topic of biologic interchangeability and its implications for the biosimilar market moving forward. Each subsequent issue of the Samsung Bioepis Biosimilar Market Report will provide a complete overview of the latest pricing and utilization trends for the entire biosimilar market along with a review of the most important topics in the biosimilar sphere. We invite you to download our first Samsung Bioepis…

04/11/2023

New combination therapy for treatment of locally advanced or metastatic urothelial cancer - 4/10/23

Recent FDA Indication Approval in Locally Advanced/Metastatic Urothelial Cancer (mUC) Important Safety Information | Full Prescribing Information including BOXED WARNING New Indication of PADCEV in Combination With Pembrolizumab Now Approved as a First-Line Treatment Option On April 3, 2023, PADCEV’s indication was expanded based on data from the EV-103 trial. PADCEV, as a single agent, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who: • have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and platinum-containing chemotherapy, or • are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy PADCEV, in combination with pembrolizumab, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who are not eligible for cisplatin-containing chemotherapy. This…

J-Code 04/10/2023

Permanent HCPCS J-Code for SPEVIGO - 3/27/23

Permanent HCPCS J-Code for SPEVIGO EFFECTIVE APRIL 1, 2023 A monoclonal IgG1 antibody for the treatment of generalized pustular psoriasis (GPP) flares in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS SPEVIGO is contraindicated in patients with severe or life-threatening hypersensitivity to spesolimabsbzo or to any of the excipients in SPEVIGO. Reactions have included drug reaction with eosinophilia and systemic symptoms (DRESS). Please see additional Important Safety Information below and full Prescribing Information , including Medication Guide . Coding for SPEVIGO* Code Type Code Description ICD-10-CM L40.1 Generalized pustular psoriasis CPT 96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour 96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure) HCPCS J Code J1747 Injection…

04/10/2023

New HCPCS Code Descriptor for J1954 Cipla USA's LEUPROLIDE ACETATE INJECTION DEPOT - 3/14/23

Effective April 1, 2023: New HCPCS Code Descript or for J1954: Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg. J1954 is a unique HCPCS code for Cipla's version of LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) and sh ould not be used for billing other leuprolide formulations. HCPCS Code HCPCS Code Descriptor NDC Number Strength WAC Per Package HCPCS Units Per Package J1954 Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg 69097-0909-50 22.5 mg $1,355.07 3 We respectfully request the update of all claims and reimbursement systems to include the new HCPCS code descriptor for J1954: Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg. effective April 1, 2023 Please contact us @ [email protected] © Copyright 2023 Cipla USA Inc. All rights reserved April 2023…

FDA Approved 03/10/2023

Now Approved: SYFOVRE (pegcetacoplan injection) - 3/2/23

Now Approved: SYFOVRE™ (pegcetacoplan injection) Email content sponsored by Apellis Pharmaceuticals, Inc. Email content sponsored by Apellis Pharmaceuticals, Inc. NOW APPROVED: The first and only treatment proven to slow lesion growth rate in GA secondary to AMD 1 SYFOVRE (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) SELECT SAFETY INFORMATION SYFOVRE is contraindicated in patients with ocular or periocular infections, and in patients with…

Now Available 03/10/2023

Now Available: Orenitram Titration Kits for Simplified Dosing - 3/1/23

Now Available: Orenitram® Titration Kits for Simplified Dosing Orenitram Titration Kits for Simplified Dosing 96 --> Orenitram Titration Kits for Simplified Dosing We are pleased to announce the availability of the Orenitram Titration Kit , designed to simplify dosing and titration so patients can reach the target dose prescribed by their healthcare provider. *De novo patients who are starting Orenitram on a TID dosing schedule are eligible for the Titration Kit. Restrictions apply. 3 MONTHLY KITS 4 WEEKLY BOXES PER MONTH 7…

Pricing 03/10/2023

Price Change for HEPLISAV-B, Hepatitis B Vaccine (Recombinant) - 2/23/23

Announcing a price change for HEPLISAV-B®, {Hepatitis B Vaccine (Recombinant), Adjuvanted} This message is being sent by www.BuyandBill.com on behalf of Dynavax Technologies Effective March 1, 2023 the pricing of HEPLISAV-B ® will change as outlined below. Please take a moment to update any of your reimbursement, billing, and ordering systems to reflect this change. HEPLISAV-B® NDC Code and Pricing: CPT Code 11 Digit NDC Code Effective Date Product Description WAC Per Package WAC Per Syringe Estimated AWP…

03/10/2023

Lamzede: New Treatment Option Available For Ultra-rare LSD - 2/22/23

New Treatment Option Available For Ultra-rare LSD We are pleased to announce the recent FDA approval of Lamzede® (velmanase alfa-tycv); a recombinant human lysosomal alpha-mannosidase indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.1 AM patients have waited a long time for a treatment option and Chiesi is proud to have it now available for them. Dosage and administration: The recommended dosage is 1mg/kg (actual body weight) administered once every week as an…

03/10/2023

J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G - 2/1/23

To: Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) Effective "> J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) From: BuyandBill.com < [email protected] > To: Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS) Effective January 1, 2023: J1932…

03/09/2023

J1954, injection, leuprolide, (Lutrate), 7.5 mg, is available for all sites of care - 1/4/23

Effective January 1, 2023: J1954 The unique HCPCS code for Cipla USA's LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) Effective January 1, 2023: J1954, injection, leuprolide, (Lutrate), 7.5 mg, is available for all sites of care. J1954 is a unique HCPCS code for Cipla's version of LEUPROLIDE ACETATE INJECTION DEPOT (Leuprolide Acetate for Depot Suspension) and sh ould not be used for billing other leuprolide formulations. HCPCS Code HCPCS Code Descriptor NDC Number Strength WAC Per Package HCPCS Units Per…

1 … 141516 17

No alerts match your filters.